美女免费一级视频在线观看

As mRNA falls out of favor, are cancer vaccines next? Oncologists worry that an area yielding new treatments will hit federal resistance. (STAT News)

The Trump administration has spoken to drugmakers about raising prices of medications abroad to cut costs in the U.S. Officials told companies that they would support international negotiations if they adopt “Most Favored Nation” drug costs. (Reuters) 

Eli Lilly’s investigational obesity pill orforglipron fell short of expectations in a late stage trial, delivering 11.2% weight loss during 72 weeks. Compared to 15% to 20% reductions from similar drugs Wegovy and Zepbound, the drug does not meet industry standards. (IndyStar) 

Novartis has approached biotech Avidity Biosciences for a potential takeover offer. Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, in a move aimed at boosting the drugmaker’s pipeline of medicines targeting rare genetic disorders. (Financial Times) 

The Food and Drug Administration launched a new program called FDA PreCheck to strengthen domestic pharmaceutical manufacturing and reduce reliance on foreign suppliers. Currently, more than half of pharmaceuticals distributed in the U.S. are manufactured overseas, with only 11% of active pharmaceutical ingredient manufacturers for FDA-approved products based in the United States. (Bloomberg)